Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abexinostat in relapsed/refractory follicular lymphoma
NCT03934567Phase 2Active, not recruiting
- Sponsor
- Xynomic Pharmaceuticals
- Start
- Apr 2020
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abexinostat in follicular lymphoma (FL), sponsored by Xynomic Pharmaceuticals. Started Apr 2020; status: active, not recruiting.
02
Drugs
abexinostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03934567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934567.